Rubicon Research Ltd (RUBICON) — shareholding pattern, promoter holding, financials and share price
About Rubicon Research Ltd (RUBICON)
Rubicon Research Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as RUBICON and on the BSE under scrip code 544578. Its ISIN is INE506V01022.
Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations. [1]
Rubicon Research Limited is a pharmaceutical company specializing in research, development, and manufacturing of specialty drugs and medical formulations for regulated markets, especially the US.
The company experienced significant financial growth, with revenue up by 51.7% and profit after tax increasing by 91.2% year-over-year in Q3 FY26. These results reflect its broad-based product revenue strategy.
Listed peers in Pharmaceuticals: Sai Life Sciences Ltd, Neuland Laboratories Ltd, Piramal Pharma Ltd, Granules India Ltd, Pfizer Ltd, Astrazeneca Pharma India Ltd.
Valuation & Returns
10 Jul 2026At ₹1,430 a share on 10 Jul 2026, Rubicon Research Ltd (RUBICON) was valued at a price-to-earnings ratio of 95.85x against an industry P/E of 36.41x and a price-to-book of 43.72x on a book value of ₹32.71 per share as of Mar 2025. Solomo computes return on equity of 45.61% and return on capital employed of 37.84% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 95.85x
- Industry P/E
- 36.41x
- P/B
- 43.72x
- EPS (TTM)
- ₹14.92
- Book value / share
- ₹32.71
- ROE
- 45.61%
- ROCE
- 37.84%
- ROA
- 17%
- Debt / equity
- 0.77x
- Dividend yield
- 0.1%
- EBITDA margin
- 23.26%
- 52-week range
- ₹571 – ₹1,468
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Rubicon Research Ltd (RUBICON) reported revenue of ₹1,754 crore, net profit of ₹247 crore and earnings per share of ₹14.95. That compares with revenue of ₹1,284 crore and net profit of ₹134 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹514 crore and net profit ₹77 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 314 | 394 | 854 | 1,284 | 1,754 |
| Net profit (₹ cr) | -67 | -17 | 91 | 134 | 247 |
| EPS (₹) | -132.39 | -33.31 | 5.98 | 8.72 | 14.95 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 32.49% | 38.98% | 50.40% |
| Profit growth | 23.18% | 115.75% | 47.63% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 59.76% of Rubicon Research Ltd (RUBICON) (down 0.1 pp QoQ), foreign institutional investors (FII) hold 7.52% and domestic institutional investors (DII) hold 9.43%. Market capitalisation was ₹23,650 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2025.
Largest disclosed public shareholders in Jun 2026: Shivanand Shankar Mankekar HUF 13.52%, Amansa Investments Ltd 3.12%, Kotak Midcap Fund 2.85%, Motilal Oswal Small Cap Fund 1.73%, Fidelity Funds - India Focus Fund 1.42%, Nomura Funds Ireland Public Limited Company- Nomura Funds Ireland - India Equity Fund 1.35%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 59.76% | - | 7.52% | 9.43% | 40.24% |
| Mar 2026 | 59.86% | - | 7.54% | 10.02% | 40.14% |
| Dec 2025 | 59.99% | - | 7.99% | 9.45% | 40.01% |